| Document |
Document Title |
|
WO/2021/202652A1 |
This application discloses Tyk-2 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, method of preparing them, and use of these compounds as therapeutic agents fo...
|
|
WO/2021/202787A1 |
The present disclosure provides aropisomers of pyridazinone derivatives of a compound of Formula 1a and Formula 1b, N-oxides or salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the disclosure. Also disclosed is a composition c...
|
|
WO/2021/202731A1 |
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combina...
|
|
WO/2021/193897A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of th...
|
|
WO/2021/188769A1 |
Compounds that inhibit HIF-2a, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse arr...
|
|
WO/2021/163519A1 |
Disclosed are compounds of Formula (1) including all geometric and stereoisomers, N-oxides, and salts thereof, wherein W, R1, R2, R3, R4, R5 m, n and p are as defined in the disclosure. Also disclosed are compositions containing the comp...
|
|
WO/2021/157591A1 |
The purpose of the present invention is to provide a method with which an aromatic heterocyclic ring-substituted difluoroacetic acid derivative can be produced using a simple and inexpensive method. The present invention relates to a m...
|
|
WO/2021/157590A1 |
The purpose of the present invention is to provide a method which is capable of producing a difluoromethyl-substituted aromatic heterocyclic compound by a simple and low-cost process. The present invention relates to a method for produ...
|
|
WO/2021/153786A1 |
The present invention provides a compound having an excellent control effect against pests. A compound represented by formula (1) of the present invention (in the formula, Q represents a group indicated by Q1 or a group indicated by Q2 (...
|
|
WO/2021/141041A1 |
Provided is a therapeutic agent and/or prophylactic agent for tauopathies that is based on the activation of voltage-gated sodium channels (Nav). The therapeutic agent and/or prophylactic agent for tauopathies has an Nav activator as an ...
|
|
WO/2021/136238A1 |
Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen o...
|
|
WO/2021/124344A1 |
The present invention relates to compound of formula I and II, or its pharmaceutically acceptable salt; wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, or -C2H5; R1 is selected from the group consisti...
|
|
WO/2021/127429A1 |
The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating ca...
|
|
WO/2021/123174A1 |
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cogni...
|
|
WO/2021/124346A1 |
The present invention relates to a compound of formula I, wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, and -C2H5; and R1 is selected from the group consisting of –H, and -CH3. The invention also ...
|
|
WO/2021/127273A1 |
Described herein are compounds of formulae (I), (lla) and (Mb) as prolyl hydroxylase inhibitors, HIF-lalpha stabilizers and PGK up regulators for use in treating inflammatory diseases, cancer or infections: Preferred compounds are e.g. t...
|
|
WO/2021/104288A1 |
The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invent...
|
|
WO/2021/105906A1 |
The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods f...
|
|
WO/2021/097110A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2021/087402A1 |
Systems and methods for flow cells are provided. Flow cells may encompass a range of fluidic devices for various applications ranging from microfluidic systems to bulk phase flow systems. Flow cells may comprise one or more components fo...
|
|
WO/2021/071983A1 |
Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.
|
|
WO/2021/071984A1 |
Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.
|
|
WO/2021/071981A1 |
Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.
|
|
WO/2021/060225A1 |
The present invention relates to compounds represented by formula (I) (in the formula, R1 represents, e.g., a substituted or unsubstituted C1-6 alkyl group, R2 represents a group represented by Ra-CO-O-CRb 2- or a group represented by Ra...
|
|
WO/2021/050945A1 |
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated b...
|
|
WO/2021/050915A1 |
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods ...
|
|
WO/2021/049522A1 |
A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q1 represents a pyrazine ring or the like; G1 represents a nitrogen atom or a carbon atom; X1 represents an alkyl group or the like; m rep...
|
|
WO/2021/044437A1 |
The invention provides certain cocrystals of Olaparib and provides novel polymorphic forms of certain cocrystals of Olaparib. In particular, cocrystals of Olaparib with fumaric acid and 3,5-dihydroxybenzoic acid are described. The invent...
|
|
WO/2021/035257A1 |
The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (IA), formula (I), and formula...
|
|
WO/2021/032161A1 |
Disclosed in the present invention are a halogen-substituted phenylate compound and applications thereof. Particularly provided are a compound shown in formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prod...
|
|
WO/2021/032033A1 |
The present invention belongs to the technical field of pesticides, and in particular relates to a pyridazinol compound, a derivative thereof, a preparation method therefor, a herbicidal composition and the use thereof. The pyridazinol c...
|
|
WO/2021/032074A1 |
The present disclosure relates to a benzamide fused aromatic ring derivative, a preparation method therefor and an application thereof in medicine. Specifically, the present disclosure relates to a benzamide fused aromatic ring derivativ...
|
|
WO/2021/020362A1 |
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...
|
|
WO/2021/018834A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, m, n and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use fo...
|
|
WO/2021/009334A2 |
The present invention relates to herbicidal substituted phenyl-pyridazine-diones and substituted phenyl-pyridazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The ...
|
|
WO/2021/009335A1 |
The present invention relates to herbicidal substituted phenyl- pyridazine-diones and substituted phenyl-pyridazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The...
|
|
WO/2021/004535A1 |
Compounds of Formula (I) or (Ia), pharmaceutically acceptable salts, stereoisomers, tautomers, solvates or prodrugs, and their use as HPK1 inhibitors are described herein, and also described are methods for preparing the compounds, and m...
|
|
WO/2020/256636A1 |
In certain aspects, the invention provides a novel crystalline form of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fl
uorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides a processe fo...
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
|
WO/2020/248065A1 |
The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemic...
|
|
WO/2020/252414A1 |
Disclosed herein are naphthoquinone derivative compounds of the formula shown below, compositions thereof, and methods of using such compounds and compositions for treating or suppressing oxidative stress disorders and/or neurodegenerati...
|
|
WO/2020/242245A1 |
The present invention relates to: a phthalazinone compound, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, comprising, ...
|
|
WO/2020/239076A1 |
Pyridazinone derivatives as thyroxine receptor-β agonists, and application thereof in preparing medicines for diseases related to thyroxine receptor-β agonists. Specifically disclosed is a compound represented by formula (I), or a phar...
|
|
WO/2020/234715A1 |
The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): (I), wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention furth...
|
|
WO/2020/228577A1 |
Provided are a pyridazinone derivative and the use thereof. By selecting specific modification groups of the pyridazinone derivative provided in the present invention having a structure as shown in formula (I), the results show that the ...
|
|
WO/2020/228823A1 |
The present invention relates to novel amide compounds of formula (I), pharmaceutical compositions thereof, methods for preparing thereof, and uses thereof, wherein the symbols are as defined in the specification.
|
|
WO/2020/221276A1 |
The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-dia
mine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as w...
|
|
WO/2020/214999A1 |
The present disclosure relates to compounds for the use of treating neurodegenerative diseases and, in particular, to compounds targeting the Abelson non-tyrosine kinase (c-Abl) protein for such treatment. The neurological disorders and ...
|
|
WO/2020/210626A1 |
Disclosed are spray-dried formulations of 4-chloro-5-(4-(4-fluoro-2- (trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-
7(6H)-yl)pyridazin-3(2H)-one, methods and compositions for making the same, and solid dosage forms comprisi...
|
|
WO/2020/198526A2 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
